Biotech

All Articles

AstraZeneca articles data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early consider the performance of its own in-house antibo...

iTeos- GSK's TIGIT celebrity reveals purposeful enhancement

.After introducing a stage 3 launch based upon positive midstage results, iTeos and also GSK are act...

More collective FDA may speed up unusual disease R&ampD: record

.The FDA ought to be extra available as well as collaborative to release a rise in commendations of ...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It's an uncommonly busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Rehabs a...

Atea's COVID antiviral fails to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually failed an additional COVID-19 test, however the biotec...

Neurocrine's bid to save schizophrenia possibility falls short

.Neurocrine Biosciences' schizophrenia system pivot has actually fallen short. The biotech was not a...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has actually made an overdue entrance to the radioligand event, paying 100 thousand euros ($...

F 2G rears $100M for second attempt to receive brand new antifungal to market

.After F2G's 1st attempt to get a new course of antifungal to market was hindered due to the FDA, th...

Moderna targets $1.1 B in R&ampD spending cuts, drops 5 systems surrounded by earnings pressures

.Moderna has actually promised to reduce R&ampD spending through $1.1 billion by 2027. The decision ...

Sanofi's $80M bet on Fulcrum dystrophy drug finishes in period 3 fail

.Simply 4 months after Sanofi bet $80 million in upfront cash on Pivot Rehabs' losmapimod, the plan ...